Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 1/2024

Open Access 05-10-2023 | Leflunomide | Case Report

Leflunomide-induced collagenous colitis: a case report and literature review

Authors: Jamie O. Yang, Sarah Dry, Guy A. Weiss

Published in: Clinical Journal of Gastroenterology | Issue 1/2024

Login to get access

Abstract

We describe a patient with rheumatoid arthritis and Hashimoto’s thyroiditis who developed chronic diarrhea and subsequently diagnosed with collagenous colitis (CC) 5 years after leflunomide initiation. Cessation of leflunomide resulted in complete resolution of diarrhea within 2 months. Although rare, leflunomide-induced colitis should be considered in patients with otherwise unexplained chronic diarrhea. Diagnosis is challenging as symptom onset can occur many years after leflunomide initiation, but diarrheal symptoms typically resolve within weeks to months of stopping the instigating drug.
Literature
1.
Schiff MH, et al. Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today (Barc). 2000;36(6):383–94.CrossRefPubMed
2.
Smolen JS, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353(9149):259–66.CrossRefPubMed
3.
Emery P, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2000;39(6):655–65.CrossRefPubMed
4.
Wiacek R, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Adv Clin Exp Med. 2012;21(3):337–42.PubMed
5.
Verschueren P, Vandooren AK, Westhovens R. Debilitating diarrhoea and weight loss due to colitis in two RA patients treated with leflunomide. Clin Rheumatol. 2005;24(1):87–90.CrossRefPubMed
6.
Tan J et al. Adverse drug reaction: rosuvastatin as a cause for ischaemic colitis in a 64-year-old woman. BMJ Case Rep. 2012.
7.
Kusnik B, Stolte M. Lymphocytic colitis under treatment with duloxetine. Z Gastroenterol. 2010;48(6):693–5.CrossRefPubMed
8.
Tome J, Kamboj AK, Pardi DS. Microscopic colitis: a concise review for clinicians. Mayo Clin Proc. 2021;96(5):1302–8.CrossRefPubMed
9.
Munch A, et al. Microscopic colitis: current status, present and future challenges: statements of the European Microscopic Colitis Group. J Crohns Colitis. 2012;6(9):932–45.CrossRefPubMed
10.
Nunez P, et al. Leflunomide as a cause of collagenous colitis: an entity to consider. Rev Esp Enferm Dig. 2021;113(10):735.PubMed
11.
Muhammad T, et al. Leflunomide-induced delayed onset colitis. Br J Hosp Med. 2021;82:1–3.CrossRef
12.
Gugenberger C, et al. Persistent diarrhea and loss of weight during therapy with leflunomide. Dtsch Med Wochenschr. 2008;133(34–35):1730–2.CrossRefPubMed
13.
Chis R, et al. A198 leflunomide-induced colitis in immunosuppressed patient with systemic lupus erythematosus and rheumatoid arthritis. J Can Assoc Gastroenterol. 2021;4:222–3.CrossRef
14.
Kwok AMF, Morosin T. Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis. Clin J Gastroenterol. 2019;12(4):310–5.CrossRefPubMed
15.
Günendi Z, et al. Long term use of leflunomide as a cause of severe diarrhea? Arch Rheumatol. 2010;25(1):041–3.CrossRef
16.
Lui J, de la Fuente J, Halland M. Colitis in a rheumatologic patient. Gastroenterology. 2020;159(6):2034–5.CrossRefPubMed
17.
You D, Yen T. Leflunomide-induced colitis. Am J Gastroenterol. 2012;107:S476.CrossRef
18.
19.
Hamdeh S, Micic D, Hanauer S. Drug-induced colitis. Clin Gastroenterol Hepatol. 2021;19(9):1759–79.CrossRefPubMed
Metadata
Title
Leflunomide-induced collagenous colitis: a case report and literature review
Authors
Jamie O. Yang
Sarah Dry
Guy A. Weiss
Publication date
05-10-2023
Publisher
Springer Nature Singapore
Published in
Clinical Journal of Gastroenterology / Issue 1/2024
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-023-01862-2

Other articles of this Issue 1/2024

Clinical Journal of Gastroenterology 1/2024 Go to the issue

Case Report

Choledochocele with hyperplastic epithelium in a patient who developed severe acute pancreatitis and underwent subtotal stomach-preserving pancreatoduodenectomy: a case report

Case Report

A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Case Report

Sporadic gastric juvenile polyposis with a novel SMAD4 nonsense mutation in a mosaic pattern

Case Report

Tissue acquisition for comprehensive genomic profiling of gallbladder cancer using a forward-viewing echoendoscope in a patient who underwent Roux-en-Y reconstruction

Case Report

Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report

Case Report

Metastatic pancreatic cancer with multiple metastases confined to the large intestine: a case report and literature review
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits